Off-target interactions as novel explantion of NSAID CV risk

Keyphrases

• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 100%
• Cardiovascular Risk 100%
• Off-target Interactions 100%
• Diclofenac 60%
• Nuclear Receptor 40%
• Naproxen 35%
• Aldosterone 30%
• Angiotensin-converting Enzyme 1 30%
• Vmax 20%
• Safety Profile 15%
• Cardiovascular Safety 15%
• Drug Interactions 10%
• Celecoxib 10%
• Rofecoxib 10%
• Michaelis-Menten 10%
• Reporter Assay 10%
• Blood Pressure 5%
• Thyroid Hormone Receptor 5%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 5%
• Comprehensive Investigation 5%
• 2-way 5%
• Nonlinear Regression 5%
• In Silico Methods 5%
• Aspirin 5%
• Fluorescence Assay 5%
• VirtualToxLab 5%
• Valdecoxib 5%
• Target Theory 5%
• Polypharmacology 5%
• Normalized Value 5%
• Trandolapril 5%
• PharmMapper 5%
• Coxibs 5%
• Luminescent Reporters 5%
• Significance of Differences 5%
• Sigma-1 Receptor 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Non-Steroidal Anti-Inflammatory Drug 100%
• Cardiovascular Risk 100%
• Diclofenac 60%
• Cell Nucleus Receptor 40%
• Naproxen 35%
• Dipeptidyl Carboxypeptidase 30%
• Aldosterone 30%
• Drug Interaction 10%
• Celecoxib 10%
• Rofecoxib 10%
• Acetylsalicylic Acid 5%
• Ibuprofen 5%
• COX-2 Inhibitor 5%
• Thyroid Hormone Receptor Beta 5%
• Valdecoxib 5%
• Trandolapril 5%